Abstract
Programmed death protein 1 (PD-1) interaction with PD-L1 deliver immunosuppressive environment for tumor growth, and its blockade with directed monoclonal antibodies (anti-PD-1/anti-PD-L1) has shown remarkable clinical outcome. Lately, their soluble counterparts, sPD-1 and sPD-L1, have been detected in plasma, and elevated levels have been associated with advanced disease, clinical stages, and worst prognosis for cancer patients. Elevated plasma levels of sPD-L1 have been correlated with worst prognosis in several studies and has displayed a persistent outlook. On the other hand, sPD-1 levels have been inconsistent in their predictive and prognostic ability. Pretherapeutic higher sPD-1 plasma levels have shown to predict advanced disease state and to a lesser extent worst prognosis. Any increase in sPD-1 plasma level post therapeutically have been correlated with improved survival for various cancers. In vitro and in vivo studies have shown sPD-1 ability to bind PD-L1 and PD-L2 and block PD-1/PD-L1 interaction. Local delivery of sPD-1 in cancer tumor microenvironment through local gene therapy have demonstrated an increase in tumor specific CD8+ T cell immunity and tumor growth reduction. It had also exhibited enhancement of T cell immunity induced by vaccination and other gene therapeutic agents. Furthermore, it may also lessen the inhibitory effect of circulating sPD-L1 and enhance the effects of mAb-based immunotherapy. In this review, we highlight various aspects of sPD-1 role in cancer prediction, prognosis, and anti-cancer immunity, as well as, its therapeutic value for local gene therapy or systemic immunotherapy in blocking the PD-1 and PD-L1 checkpoint interactions.
Highlights
Adaptive immune system comprising T cells (CD 4+ and CD 8+ T cells) and B cells is capable of destroying and eliminating any foreign harmful invader while sparing normal healthy cells through self-tolerance [1]
Blockade of PD-1/PD-L1 inhibitory immune checkpoint have revolutionized the cancer therapy paradigm; this particular checkpoint pathway has been the subject of intense investigations
Expression, regulation, and interaction of PD-1 and its ligands have enhanced our understanding of how costimulatory and coinhibitory molecules have been exploited by cancer cells for immune evasion
Summary
Adaptive immune system comprising T cells (CD 4+ and CD 8+ T cells) and B cells is capable of destroying and eliminating any foreign harmful invader while sparing normal healthy cells through self-tolerance [1]. Differentiation of CD4+ T cells into Fox3+ regulatory T cells is promoted [10] As a result, these coinhibitory pathways have been proven to be the key mechanism for tumor immune evasion as high and sustained PD-1 & PD-L1/L2 expression is often reported in cancer and chronic infections [11, 12]. These coinhibitory pathways have been proven to be the key mechanism for tumor immune evasion as high and sustained PD-1 & PD-L1/L2 expression is often reported in cancer and chronic infections [11, 12] Blocking this pathway has shown improvements in T cells functionality and cancer patients’ survival [13,14,15]. PD-1/PD-L1 interaction leads to a chain of intracellular events in T cells, which culminate in T cell inhibition and tumor immune tolerance
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
